Harmonization status of procalcitonin measurements: what do comparison studies and EQA schemes tell us? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Chemistry and Laboratory Medicine Année : 2021

Harmonization status of procalcitonin measurements: what do comparison studies and EQA schemes tell us?

Jens Pfannkuche
  • Fonction : Auteur
Philipp Schuetz
  • Fonction : Auteur
Marc Thelen
  • Fonction : Auteur
Gunnar Nordin
  • Fonction : Auteur
Eline van Der Hagen
  • Fonction : Auteur
Patricia Kaiser
  • Fonction : Auteur
Dagmar Kesseler
  • Fonction : Auteur
Tony Badrick
  • Fonction : Auteur
Bernard Poggi
  • Fonction : Auteur
Ulla Tiikkainen
  • Fonction : Auteur
Gareth Davies
  • Fonction : Auteur
Anja Kessler
  • Fonction : Auteur
Mario Plebani
  • Fonction : Auteur

Résumé

Abstract Sepsis represents a global health priority because of its high mortality and morbidity. The key to improving prognosis remains an early diagnosis to initiate appropriate antibiotic treatment. Procalcitonin (PCT) is a recognized biomarker for the early indication of bacterial infections and a valuable tool to guide and individualize antibiotic treatment. To meet the increasing demand for PCT testing, numerous PCT immunoassays have been developed and commercialized, but results have been questioned. Many comparison studies have been carried out to evaluate analytical performance and comparability of results provided by the different commercially available immunoassays for PCT, but results are conflicting. External Quality Assessment Schemes (EQAS) for PCT constitute another way to evaluate results comparability. However, when making this comparison, it must be taken into account that the variety of EQA materials consist of different matrices, the commutability of which has not yet been investigated. The present study gathers results from all published comparison studies and results from 137 EQAS surveys to describe the current state-of-the-art harmonization of PCT results. Comparison studies globally highlight a significant variability of measurement results that nonetheless seem to have a moderate impact on medical decision-making. For their part, EQAS for PCT provides highly discrepant estimates of the interlaboratory CV. Due to differences in commutability of the EQA materials, the results from different peer groups could not be compared. To improve the informative value of the EQA data, the existing limitations such as non-harmonized conditions and suboptimal and/or unknown commutability of the EQA materials have to be overcome. The study highlights the need for commutable reference materials that could be used to properly evaluate result comparability and possibly standardize calibration, if necessary. Such an initiative would further improve the safe use of PCT in clinical routine.

Domaines

Chimie
Fichier principal
Vignette du fichier
10.1515_cclm-2021-0566.pdf (751.16 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03335225 , version 1 (29-11-2021)

Identifiants

Citer

Huu-Hien Huynh, Amandine Bœuf, Jens Pfannkuche, Philipp Schuetz, Marc Thelen, et al.. Harmonization status of procalcitonin measurements: what do comparison studies and EQA schemes tell us?. Clinical Chemistry and Laboratory Medicine, 2021, 59 (10), pp.1610-1622. ⟨10.1515/cclm-2021-0566⟩. ⟨hal-03335225⟩
47 Consultations
69 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More